Macrocyclic oximyl hepatitis C protease inhibitor

Abstract

The present invention discloses a compound of formula I which inhibits serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compound of the present invention interferes with the life cycle of the hepatitis C virus and is also useful as antiviral agent. The present invention further relates to pharmaceutical composition comprising the aforementioned compound for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compound of the present invention.